How to Build (and Sustain) a Quality-Centric Culture with Chris Masterson
Episode
43 min
Read time
2 min
Topics
Investing, Fundraising & VC, Leadership
AI-Generated Summary
Key Takeaways
- ✓Culture Timeline & Accountability: Shifting organizational culture realistically takes three to five years and requires senior leadership actively living company values — not just stating them. Progress requires incentivizing aligned behaviors and disincentivizing violations. Key drivers include consistency, repetition, patience, and perseverance. Without executive modeling, cultural transformation stalls regardless of budget or initiative size.
- ✓Quality Culture Measurement: Rather than building custom metrics, use the ANSI PDA Standard 06-2025 (Parenteral Drug Association) quality culture assessment tool, freely available at pda.org. This semi-quantitative survey benchmarks current culture, identifies specific improvement areas, and tracks progress over time. Gartner also offers a comparable benchmarking survey as an alternative resource.
- ✓ROI Justification for Quality Investment: When justifying quality culture budgets to finance or the C-suite, frame returns as compliance improvement, waste reduction via lean six sigma, and regulatory risk avoidance. A single FDA consent decree can cost a pharmaceutical company $500 million or more — making proactive quality investment substantially cheaper than reactive remediation after a warning letter or enforcement action.
- ✓Inspection Readiness Over Remediation: After a difficult FDA inspection, convert post-inspection remediation meetings into permanent Inspection Readiness Steering Committees. This reframe shifts the organization from reactive problem-fixing to continuous proactive risk identification and mitigation. Supplement with external mock inspections from qualified consultants to surface compliance gaps before regulators do.
- ✓Contract Manufacturer Responsibility: Holding a market authorization means full regulatory responsibility for every contract manufacturer and contract testing lab in the supply chain — regardless of which FDA district oversees that facility. Organizations cannot transfer compliance accountability to vendors. Proactive oversight, auditing, and quality agreements are the only mechanisms to manage this risk effectively.
What It Covers
Chris Masterson, SVP and Chief Quality Officer at Tomar with 36 years in biopharma, outlines how organizations build and sustain quality-centric cultures. He covers leadership accountability, realistic three-to-five year timelines, ROI justification, measurement frameworks including the ANSI PDA Standard 06-2025, and learning from regulatory failures.
Key Questions Answered
- •Culture Timeline & Accountability: Shifting organizational culture realistically takes three to five years and requires senior leadership actively living company values — not just stating them. Progress requires incentivizing aligned behaviors and disincentivizing violations. Key drivers include consistency, repetition, patience, and perseverance. Without executive modeling, cultural transformation stalls regardless of budget or initiative size.
- •Quality Culture Measurement: Rather than building custom metrics, use the ANSI PDA Standard 06-2025 (Parenteral Drug Association) quality culture assessment tool, freely available at pda.org. This semi-quantitative survey benchmarks current culture, identifies specific improvement areas, and tracks progress over time. Gartner also offers a comparable benchmarking survey as an alternative resource.
- •ROI Justification for Quality Investment: When justifying quality culture budgets to finance or the C-suite, frame returns as compliance improvement, waste reduction via lean six sigma, and regulatory risk avoidance. A single FDA consent decree can cost a pharmaceutical company $500 million or more — making proactive quality investment substantially cheaper than reactive remediation after a warning letter or enforcement action.
- •Inspection Readiness Over Remediation: After a difficult FDA inspection, convert post-inspection remediation meetings into permanent Inspection Readiness Steering Committees. This reframe shifts the organization from reactive problem-fixing to continuous proactive risk identification and mitigation. Supplement with external mock inspections from qualified consultants to surface compliance gaps before regulators do.
- •Contract Manufacturer Responsibility: Holding a market authorization means full regulatory responsibility for every contract manufacturer and contract testing lab in the supply chain — regardless of which FDA district oversees that facility. Organizations cannot transfer compliance accountability to vendors. Proactive oversight, auditing, and quality agreements are the only mechanisms to manage this risk effectively.
Notable Moment
Masterson recalled being forced to voluntarily recall 106 product lots following an FDA inspection — while the contract manufacturer producing the same product on the same line recalled nothing, because they operated under a different FDA district. The episode reframed how he approaches contract manufacturer oversight permanently.
Episode Transcript
Hello, everyone. Welcome to the Life Science Rundown. This is Nicholas Catman with the FDA group. Before we jump into our discussion for today, just a little bit about the FDA group. We help life science companies in the areas of quality assurance, regulatory affairs, clinical operations, commissioning, qualification, and validation, as well as pharmacovigilance. We offer three different engagement models, which are consulting, staff augmentation, and full time employer recruitment. So if you're finding yourself in need, just head over to the fdagroup.com to check us out and get in touch. So today, I'm speaking with Chris Masterson. Hey, Chris. Hey, Nicholas. How are you doing today? I'm doing great. Thank you for joining me today. Thank you. Okay. Before we jump into our topic, would you kindly introduce yourself? Yeah. So my name is Chris Masterson. I am the senior vice president and chief quality officer for Tomar. I've worked in the biopharmaceutical industry for the last, let's see, thirty six years. Started in 1989, way before some of you were born likely, and married, have two children, two beautiful children, care about everybody. And I'm a I'm almost 60 years old now, and I'm on the, the twilight of my career. What I'm trying to do now is really better develop the talent for the future, of biopharmaceuticals. Okay. Well, that's a great, sequitur into the topic. So our topic for today is how can biopharmaceutical organizations build and maintain a strong quality culture accounting for time, leadership support, measurable results, key skills, and the internal and external factors that drive or hinder success. So there's a a lot to uncover there. Why don't we start here? So how would you define a quality driven culture, and why is it essential for long term success? Yeah. I'll start with my definition of culture, and then I'll get into the definition of what other people think. Okay. So my definition of culture is the way things are done around here. You know, some companies that I've worked with are very family oriented. Some are authoritarian. Some are friendly. Some are accountable, hardworking, driven, fun, etcetera. I think that the way things are done around here is what I define as culture. The dictionary defines it a little differently. They say the shared values, attitudes, and practices, that characterize an organization and influence how its members behave and interact. I would say quality driven is about how people perceive doing things right the first time. In pharmaceuticals, quality is typically about GXP compliance where GXP equals, the x is algebraic, and it equals good manufacturing practices, good clinical practices, good distribution practices, etcetera. And it's about g x GXP compliance. It's really not about quality. Quality originally as defined was really Deming, Duran, Crosby, and all about operational excellence, lean six sigma, that sort of thing. But in the pharmaceutical industry, it's more about, the the compliance of the organization, the biopharmaceutical organization. So I recently helped, write a …
Get the full transcript (6,604 words) + summary by email — free
One-time email with the complete transcript and AI summary of this episode. No account needed.
One email, no spam. We’ll also show you what SignalCast does.
You just read a 3-minute summary of a 40-minute episode.
Get The Life Science Rundown summarized like this every Monday — plus up to 2 more podcasts, free.
Pick Your Podcasts — FreeKeep Reading
More from The Life Science Rundown
QA Is Not a Gate — It’s a Technical Partner, with Dr. Andrea Bell
Sep 1 · 28 min
The Vergecast
Apple’s got a new CEO: The Vergecast Livestream
Apr 20
More from The Life Science Rundown
Managing AI Risk Across Global Quality Systems
Aug 17 · 32 min
Techmeme Ride Home
(BNS) How Snowflake Wrote The GTM Playbook
Oct 4
Books, tools, and gear mentioned in this episode
SignalCast may earn commission on purchases via these links.
Tools
- Gartner Quality Culture Benchmarking SurveyRecommended
by Gartner
“Gartner also offers a comparable benchmarking survey as an alternative resource.”
other
- ANSI PDA Standard 06-2025Recommended
by Parenteral Drug Association
“Rather than building custom metrics, use the ANSI PDA Standard 06-2025 (Parenteral Drug Association) quality culture assessment tool, freely available at pda.org. This semi-quantitative survey benchmarks current culture, identifies specific improvement areas, and tracks progress over time.”
More from The Life Science Rundown
We summarize every new episode. Want them in your inbox?
QA Is Not a Gate — It’s a Technical Partner, with Dr. Andrea Bell
Managing AI Risk Across Global Quality Systems
The Case for Engaging Regulatory Early
Why Quality and R&D Default to Conflict (and How to Fix It)
Leading Through the AI Shift with ASQ's CEO Sid Bhatnagar
Similar Episodes
Related episodes from other podcasts
The Vergecast
Apr 20
Apple’s got a new CEO: The Vergecast Livestream
Techmeme Ride Home
Oct 4
(BNS) How Snowflake Wrote The GTM Playbook
NVIDIA AI Podcast
Jul 9
How Bristol Myers Squibb Is Accelerating Drug Development With AI - Ep. 264
Everything Everywhere Daily
Sep 11
The Immovable Ladder of Jerusalem
Practical AI
Sep 3
Less about Models; More about Architecture
Explore Related Topics
This podcast is featured in Best Science Podcasts (2026) — ranked and reviewed with AI summaries.
Read this week's Investing & Markets Podcast Insights — cross-podcast analysis updated weekly.
You're clearly into The Life Science Rundown.
Every Monday, we deliver AI summaries of the latest episodes from The Life Science Rundown and 192+ other podcasts. Free for one show.
Start My Monday DigestNo credit card · Unsubscribe anytime